OncLive

Most Recent

Nivolumab/Ipilimumab Significantly Improves OS in Malignant Pleural Mesothelioma

August 9th 2020

By Hayley Virgil

Nivolumab plus ipilimumab significantly improved overall survival versus chemotherapy in the first-line treatment of patients with unresectable malignant pleural mesothelioma.

Ensartinib Significantly Prolongs PFS Over Crizotinib in ALK+ NSCLC

August 8th 2020

By Kristi Rosa

Ensartinib showed a significant improvement in progression-free survival over crizotinib with a favorable safety profile in patients with ALK-positive non–small cell lung cancer.

Sintilimab/Pemetrexed Regimen Significantly Improves PFS in Advanced NSCLC

August 8th 2020

By Gina Columbus

Sintilimab injection plus pemetrexed and platinum-based therapy led to a statistically significant improvement in progression-free survival compared with chemotherapy alone as a first-line treatment for patients with locally advanced or metastatic nonsquamous non–small cell lung cancer.

FDA Grants Pedmark Priority Review for Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors

August 7th 2020

By Kristi Rosa

The FDA has granted a priority review designation to a new drug application for a unique formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity in patients from 1 month to less than 18 years of age with localized, nonmetastatic, solid tumors.

Longer Follow-Up Data Confirms Cemiplimab’s Utility in CSCC, Though Challenges Remain

August 7th 2020

By Jessica Hergert

Anna C. Pavlick, DO, discusses the benefit of cemiplimab for patients with cutaneous squamous cell carcinoma (CSCC), the impact of these longer follow-up data, rare, but notable, toxicities that can arise with the agent, and ongoing research efforts aimed at increasing responses to immunotherapy in the CSCC space.

Latest Videos

All Content

x